An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini.
Alemayehu Lelisa DugaSibongile MagongoSiphesihle NhlabatsiDenis O LadwarLinda HärmarkLeàn RolfesPublished in: AIDS research and therapy (2022)
Cases that support causality between dolutegravir containing regimen and hyperglycaemia were found. These cases were mainly serious. Based on these findings it is recommended that healthcare professionals (HCPs) actively screen all patients for risk factors of hyperglycaemia before DTG initiation. In addition, it is important that HCPs are aware of the possible association between DTG and hyperglycaemia.
Keyphrases
- antiretroviral therapy
- risk factors
- end stage renal disease
- hiv infected
- ejection fraction
- hiv positive
- human immunodeficiency virus
- hiv infected patients
- chronic kidney disease
- hepatitis c virus
- hiv aids
- prognostic factors
- emergency department
- high throughput
- men who have sex with men
- south africa
- single cell
- combination therapy
- drug administration
- drug induced